The use of lipopolysaccharide (LPS)-binding protein (LBP) to treat Parkinson’s Disease (AD) by reducing hypercoagulation (exaggerated blood clotting) commonly associated with this disease.
Brief description
The use of lipopolysaccharide (LPS)-binding protein (LBP) to treat Parkinson’s Disease (AD) by reducing hypercoagulation (exaggerated blood clotting) commonly associated with this disease.
Unique Characteristics
The researchers responsible for the development of this innovation have recently shown that there is a bacterial component involved in the aetiology of PD. Multiple research studies have shown that the pyrogenic bacterial wall component, LPS (from gram negative bacteria) is a potent inflammagen.
(elicits an inflammatory response that causes hypercoagulation in a multitude of inflammatory conditions. LBP naturally occurs in the human body, and in diseases such as PD, the production of LBP is reduced. Consequently, in the context of systemic inflammation,
excess LPS cannot be bound and cleared to a sufficient degree,resulting in a hypercoagulable state. This innovation proposes the use of LBP to treat hypercoagualation in inflammatory conditions such as PD.
Target Market
This innovation is targeted to the following industries:
- Pharmaceutical companies
- Biotechnology companies
- Clinical trials companies
